EE200400056A - 2-alkoksüfenüül-asendatud imidasotriasinoonide kasutamine - Google Patents

2-alkoksüfenüül-asendatud imidasotriasinoonide kasutamine

Info

Publication number
EE200400056A
EE200400056A EEP200400056A EEP200400056A EE200400056A EE 200400056 A EE200400056 A EE 200400056A EE P200400056 A EEP200400056 A EE P200400056A EE P200400056 A EEP200400056 A EE P200400056A EE 200400056 A EE200400056 A EE 200400056A
Authority
EE
Estonia
Prior art keywords
upto
alkoxycarbonyl
cooh
alkyl
diseases
Prior art date
Application number
EEP200400056A
Other languages
English (en)
Inventor
Niew�hner Ulrich (surnud)
Bischoff Erwin
Haning Helmut
Rahbar Afssaneh
Bandel Tiemo-Joerg
Barth Wolfgang
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of EE200400056A publication Critical patent/EE200400056A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
EEP200400056A 2001-07-23 2002-07-17 2-alkoksüfenüül-asendatud imidasotriasinoonide kasutamine EE200400056A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10135815A DE10135815A1 (de) 2001-07-23 2001-07-23 Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
PCT/EP2002/007959 WO2003011262A2 (de) 2001-07-23 2002-07-17 Verwendung von 2-alkoxyphenyl-substituierten imidazotriazinonen zur behandlung von erkrankungen, die im zusammenhang mit cgmp-regulierten vorgängen stehen

Publications (1)

Publication Number Publication Date
EE200400056A true EE200400056A (et) 2004-04-15

Family

ID=7692784

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200400056A EE200400056A (et) 2001-07-23 2002-07-17 2-alkoksüfenüül-asendatud imidasotriasinoonide kasutamine

Country Status (28)

Country Link
US (3) US6930108B2 (et)
EP (2) EP1733728A3 (et)
JP (1) JP2005504751A (et)
KR (1) KR20040032865A (et)
CN (1) CN1649593A (et)
AT (1) ATE442144T1 (et)
AU (1) AU2002319296B2 (et)
BG (1) BG108533A (et)
BR (1) BR0211359A (et)
CA (1) CA2454414A1 (et)
CO (1) CO5560536A2 (et)
CZ (1) CZ2004128A3 (et)
DE (2) DE10135815A1 (et)
EC (1) ECSP044956A (et)
EE (1) EE200400056A (et)
ES (1) ES2330418T3 (et)
HR (1) HRP20040065A2 (et)
HU (1) HUP0500734A3 (et)
IL (1) IL159840A0 (et)
MA (1) MA26128A1 (et)
MX (1) MXPA04000675A (et)
NO (1) NO20040294L (et)
NZ (1) NZ530703A (et)
PL (1) PL373392A1 (et)
RU (1) RU2321406C9 (et)
SK (1) SK442004A3 (et)
UA (1) UA76997C2 (et)
WO (1) WO2003011262A2 (et)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
JP2006219374A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
JP2008536888A (ja) 2005-04-19 2008-09-11 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺高血圧症の治療のためのロフルミラスト
EP2521721B1 (en) 2009-12-30 2014-10-01 Shanghai Fochon Pharmaceutical Co. Ltd 3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
AT512084A1 (de) * 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
EP3554506B1 (en) * 2016-12-16 2021-04-28 Cystic Fibrosis Foundation Bycyclic heteroaryl derivatives as cftr potentiators
CN113461694A (zh) * 2021-08-05 2021-10-01 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用
CN113583003A (zh) * 2021-08-05 2021-11-02 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791025A (fr) 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
US4479210A (en) * 1982-11-19 1984-10-23 U.S. Philips Corporation Record-disc player
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
JPH11503445A (ja) * 1995-04-10 1999-03-26 藤沢薬品工業株式会社 ｃＧＭＰ−ＰＤＥ阻害剤としてのインドール誘導体
DE69635135T2 (de) * 1995-12-28 2006-07-06 Fujisawa Pharmaceutical Co., Ltd. Benzimidazolderivate
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
ES2386420T3 (es) * 1997-11-12 2012-08-20 Bayer Pharma Aktiengesellschaft Imidazotriazinonas sustituidas con fenilo en la posición 2 como inhibidores de fosfodiesterasas
DE19812462A1 (de) * 1998-03-23 1999-09-30 Bayer Ag 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid
ES2212383T3 (es) * 1997-12-12 2004-07-16 Osi Pharmaceuticals, Inc. Derivados de n-bencil-3-indenilacetamidas para el tratamiento de neoplasias.
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
DE19827640A1 (de) 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
FR2792634B1 (fr) * 1999-04-20 2001-06-01 Synthelabo Derives de 2-alcoxy-cyclobutene-3,4-dione leur preparation et leur application en therapeutique
IL130968A (en) * 1999-07-15 2002-12-01 Shmuel Simon Pharmaceutical composition comprising sildenafil or its analogs, useful for the treatment of tinnitus and hearing loss
AU775102B2 (en) * 1999-09-13 2004-07-15 David M. Swope Composition and method for decreasing neurologic symptomatology
DE19943815A1 (de) * 1999-09-14 2001-03-15 Merck Patent Gmbh Verwendung von Thienopyrimidinen
CA2323008C (en) 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
EP1220672B1 (de) * 1999-10-12 2006-10-04 Lilly Icos LLC Arzneimittel zur behandlung von neuropathien
IL139073A0 (en) * 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
CA2406947A1 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
US20020006926A1 (en) * 2000-04-19 2002-01-17 Roylance H. H. Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease
KR20030023747A (ko) * 2000-08-11 2003-03-19 화이자 인코포레이티드 인슐린 저항성 증후군의 치료
AU2001286832A1 (en) * 2000-08-30 2002-03-13 Lilly Icos Llc Method for treatment of migraine using PDE5 inhibitors
GB0025782D0 (en) * 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
CA2436576A1 (en) * 2001-02-02 2002-08-08 Pfizer Inc. Treatment of diabetes mellitus using vardenafil
DE10107639A1 (de) * 2001-02-15 2002-08-22 Bayer Ag 2-Alkoxyphenyl-substituierte Imidazotriazinone
ES2278927T3 (es) * 2001-05-09 2007-08-16 Bayer Healthcare Ag Nuevo uso de imidazotriazinonas de 2-(2-etoxi-5-(4-metil-piperazin-1-sulfonil)-fenil)-5-metil-7-propil-3h-imidazo(5,1-f)(1,2,4)triazin-4-ona.
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
JP2005527510A (ja) * 2002-03-06 2005-09-15 セレジー ファーマシューティカルズ インコーポレーティッド 癌の治療において一酸化窒素模倣体を使用するための製剤および方法

Also Published As

Publication number Publication date
DE50213840D1 (de) 2009-10-22
NZ530703A (en) 2006-06-30
RU2004105265A (ru) 2005-04-20
MA26128A1 (fr) 2004-04-01
US20080085897A1 (en) 2008-04-10
CZ2004128A3 (cs) 2004-08-18
JP2005504751A (ja) 2005-02-17
CA2454414A1 (en) 2003-02-13
CN1649593A (zh) 2005-08-03
SK442004A3 (en) 2004-06-08
DE10135815A1 (de) 2003-02-06
HUP0500734A3 (en) 2005-12-28
IL159840A0 (en) 2004-06-20
WO2003011262A2 (de) 2003-02-13
US7276504B2 (en) 2007-10-02
WO2003011262A3 (de) 2004-05-27
RU2321406C9 (ru) 2009-03-27
HRP20040065A2 (en) 2004-12-31
US20050234022A1 (en) 2005-10-20
ATE442144T1 (de) 2009-09-15
KR20040032865A (ko) 2004-04-17
BG108533A (bg) 2005-02-28
EP1733728A3 (de) 2007-03-21
EP1474150B1 (de) 2009-09-09
HUP0500734A2 (hu) 2005-11-28
ES2330418T3 (es) 2009-12-10
US20040235838A1 (en) 2004-11-25
BR0211359A (pt) 2004-07-13
MXPA04000675A (es) 2004-11-22
EP1733728A2 (de) 2006-12-20
EP1474150A2 (de) 2004-11-10
NO20040294L (no) 2004-01-22
UA76997C2 (en) 2006-10-16
PL373392A1 (en) 2005-08-22
RU2321406C2 (ru) 2008-04-10
CO5560536A2 (es) 2005-09-30
AU2002319296B2 (en) 2007-08-30
US6930108B2 (en) 2005-08-16
ECSP044956A (es) 2004-02-26

Similar Documents

Publication Publication Date Title
EE200400056A (et) 2-alkoksüfenüül-asendatud imidasotriasinoonide kasutamine
RU2429226C2 (ru) Ингибиторы пролилгидроксилазы и способы их применения
US9409902B2 (en) Modulators of HEC1 activity and methods therefor
ES2387388T3 (es) Compuesto de adenina y uso del mismo
CN102203063B (zh) 咔唑化合物及其治疗用途
JP5295230B2 (ja) 粘液分泌の刺激剤としての３’，４’，５−トリメトキシフラボン誘導体、その方法、および上記化合物を含んでなる医薬組成物
US20130281397A1 (en) Treatment of diseases by epigenetic regulation
US9938252B2 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
TW200406202A (en) Inhibitors of cyclin-dependent kinases and their use
PT2287155E (pt) Composto de aciltioureia ou um seu sal, e sua utilização
US5990117A (en) Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
CN110240557A (zh) 吡咯烷酰胺衍生物及其用途
Cuevas et al. Therapeutic response of rosacea to dobesilate
CN116963727A (zh) 用于治疗眼部病症的药剂
KR20140056164A (ko) 신규 푸라논 유도체
Du et al. Novel substituted 4-(Arylethynyl)-Pyrrolo [2, 3-d] pyrimidines negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 5 (mGlu5) Treat depressive disorder in mice
CN118696029A (zh) 化合物
CN111072604B (zh) α-氨基酰胺衍生物及其用途
CN108912029B (zh) 含氮杂环酰胺衍生物及其用途
CN112010818A (zh) 吗啉酰胺衍生物及其用途
JP2021017405A (ja) 色素性乾皮症及び色素性乾皮症に起因する症状の予防／改善剤
US20060252780A1 (en) Fused pyrimidine derivatives
CN115397423A (zh) 用于治疗mps1的组合疗法
KR20230081602A (ko) Bet 단백질을 저해하는 신규한 카르복스아마이드 리독스 유도체 및 이를 이용한 안과질환 예방 및 치료용 조성물
JP2024028808A (ja) 皮膚障害の治療